Procaps Group
Manufacturing · 5K - 10K Employees
View Company Info for Free
Overview
Phone Number
+356 79956138Website
www.procapsgroup.comRevenue
$414.1 MillionStock Symbol
PROCFIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Procaps Group
Procaps Group is a pharmaceutical manufacturer founded in 2021 with global operations across North America, South America, and Europe. The company specializes in developing and producing pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. Procaps Group focuses on creating innovative healthcare products while maintaining a significant presence in international markets.Explore more
Procaps Group Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Procaps Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Procaps Group had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Procaps Group has new funding data
Check out if Procaps Group is spiking on competitors!
Check if Procaps Group has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Procaps Group recently announced quarterly report
Website visits: Recent activity has been detected on your website
Procaps Group, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Procaps Group
Product Launch: Get notified when Procaps Group launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Procaps Group is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Procaps Group is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Procaps Group.
Procaps Group financials insights
Gather financial insights about Procaps Group, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$130M
Procaps Group Tech Stack
A closer look at the technologies used by Procaps Group
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Procaps Group News & Media
Greenberg Traurig Advises Procaps Group in Transformational $130 Million Equity Investment, $209 Million Debt Restructuring in Latin America
Global law firm Greenberg Traurig, LLP advised Procaps Group, a leading integrated Latin American pharmaceutical and health care company, in its $130 million equity investment, comprehensive debt restructuring of approximately $209 million, and strategic leadership transition. MIAMI,...Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced GovernanceProcaps Group Receives Delisting Notice From Nasdaq
MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to delist the Company’s ordinary shares on Nasdaq. The delisting is a result of the Company’s failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(Procaps Group Receives Additional Delinquency Letter
MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) of an additional filing delinquency relating to the Company’s interim financial statements for the period ended June 30, 2024.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Procaps Group
Sign Up For FreeTo access detailed company insights
Procaps Group is a pharmaceutical manufacturer founded in 2021 with global operations across North America, South America, and Europe. The company specializes in developing and producing pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. Procaps Group focuses on creating innovative healthcare products while maintaining a... Read More
